

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

Strasbourg, France, May 4, 2026, 5:45 p.m. CET – **Transgene (Euronext Paris: TNG)**, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene's shareholders is available.

The notice of meeting, comprising the agenda and the draft resolutions, was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) no. 44 of April 13, 2026 and no. 53 of May 4, 2026.

These notices include information on how to attend and vote at the General Meeting.

The General Meeting will be held on May 22, 2026, at 11:00 am CET, at Transgene's headquarters in Illkirch-Graffenstaden (France).

It will be broadcast live in French (<https://transgene.engagestream.euronext.com/2026-05-22-ag>), and the video will also be available later within the time period provided for by the regulations on the Company's website (www.transgene.com under "Investors - Shareholders' Meeting").

The procedures and rules relative to the holding of this shareholder meeting, as well as the exercise of the right to request documents and submit written questions, are set out in the notice of meeting published on April 13 and May 4, 2026 and are also posted at www.transgene.com/#AG.

Contacts

Transgene:

Media:

Caroline Tosch

Corporate and Scientific Communications Manager

+33 (0)3 68 33 27 38

communication@transgene.fr

MEDiSTRAVA

Frazer Hall/Sylvie Berrebi

+ 44 (0) 203 928 6900

transgene@medistrava.com

Investors & Analysts:

Lucie Larguier

Chief Financial Officer (CFO)

Nadege Bartoli

Investor Relations Analyst
and Financial Communications Officer

+33 (0)3 88 27 91 00/03

investorrelations@transgene.fr

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the *myvac*® platform, demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers (HNSCC – Head and neck squamous cell carcinoma). The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel immunotherapies.

With Transgene's *myvac*® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

Additional information about Transgene is available at: www.transgene.com

Follow us on LinkedIn: [@Transgene](#) — Bluesky: [@Transgene](#) — X: [@TransgeneSA](#)

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.